Results 131 to 140 of about 3,429 (181)
Clinical and Translational Medicine, Volume 16, Issue 8, August 2026.
Chaofei Gao +3 more
wiley +1 more source
Asia-Pacific Journal of Clinical Oncology, Volume 22, Issue 4, Page 564-572, August 2026.This retrospective study of patients with small, node‐negative HER2+ breast cancer found favorable 5‐year invasive disease‐free survival rates—93% for pT1mic/a disease and 100% for pT1b disease. Trastuzumab was administered to 66% of patients and was associated with larger tumor size and higher histologic grade.
Yuanyuan Xue +5 more
wiley +1 more source
British Journal of Pharmacology, Volume 183, Issue 16, Page 4512-4531, August 2026.The G protein–coupled receptor (GPCR) superfamily consists of the most common targets of approved drugs. Targeting GPCRs offers appealing avenues for therapeutic development. Antibodies and their fragments, such as single‐domain antibodies (VHHs or nanobodies), have emerged as useful alternatives to small molecule pharmacophores as building blocks in ...
Shivani Sachdev, Ross W. Cheloha
wiley +1 more source
Cancer Science, Volume 117, Issue 8, Page 2098-2114, August 2026.Chemotherapy combined with nivolumab reshapes the gastric cancer tumor microenvironment (TME) and is accompanied by an enrichment of reduced cytotoxicity NK (RC‐NK) cells. Rather than acting as classical cytotoxic effectors, these RC‐NK cells appear to shape the TME by promoting an immunostimulatory circuit that engages adaptive immunity.
Takuya Nakatsuru +24 more
wiley +1 more source
Cancer Science, Volume 117, Issue 8, Page 2115-2131, August 2026.PD‐1 blockade combined with chemotherapy induces MHC‐II+ inflammatory neutrophils in gastric cancer, which engage in dynamic crosstalk with macrophages to remodel the tumor microenvironment toward a pro‐inflammatory state, thereby amplifying antitumor immune responses.
Keita H. Nagaoka +24 more
wiley +1 more source
Cancer Science, Volume 117, Issue 8, Page 2305-2316, August 2026.An interstitial lung disease model for DXd antibody‐drug conjugates was established in cynomolgus monkeys by weekly dosing of a non‐targeting DXd ADC. Integrated analysis of bronchoalveolar lavage fluid–derived extracellular vesicle proteomics and lung single‐cell RNA sequencing reveals cell‐type‐resolved molecular features of DXd ADC‐related lung ...
Kazuyoshi Kumagai +5 more
wiley +1 more source
Human Pharmacokinetic Prediction of Antibody‐Drug Conjugates Using Human FcRn Transgenic Mice
Clinical and Translational Science, Volume 19, Issue 8, August 2026.ABSTRACT Antibody‐drug conjugates (ADCs) have progressed significantly in recent years, particularly in the oncology field. However, predicting human pharmacokinetics (PK) of ADCs in the early stages of drug development remains challenging. Human neonatal Fc receptor (FcRn) transgenic mice have been established as a reliable pre‐clinical PK model for ...
Keitaro Nakagawa, Kenta Haraya
wiley +1 more source
Pharmacoepidemiology and Drug Safety, Volume 35, Issue 8, August 2026.
Soko Setoguchi, Sean Hennessy
wiley +1 more source
Clinical and Translational Science, Volume 19, Issue 8, August 2026.ABSTRACT Omics biomarkers comprise several molecular entities, including genomic, epigenomic, transcriptomic, proteomic, and metabolomic signatures. They play an essential role in oncology drug development and clinical settings by enabling personalized medicine.
Mai Mehanna +8 more
wiley +1 more source
World Health Organization classification of tumours of the breast 6th edition 2026
Histopathology, Volume 89, Issue 2, Page 199-218, August 2026.The 6th edition of the World Health Organization Classification of Breast Tumours introduces changes based on recent advances in our understanding of breast biology, developments in diagnostic modalities, identification of specific molecular targets and new treatment regimes.
Cecily Quinn +47 more
wiley +1 more source